Xeris Biopharma Holdings, Inc. XERS
Updated: 17 Jun 2026
No signal published yet
We already track Xeris Biopharma Holdings and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Xeris Biopharma Holdings, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Xeris Biopharma Holdings free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 11, 2026, Xeris announced a private exchange agreement to retire approximately $23 million of its 8.00% Convertible Senior Notes due 2028 using a combination of cash and common stock. This transaction is expected to reduce annual interest expenses by approximately $2 million. The company also recently raised its full-year 2026 revenue guidance to a range of $380 million to $390 million.
What Firelda Watch includes for Xeris Biopharma Holdings, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Xeris Biopharma Holdings, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Xeris Biopharma Holdings free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more